Keep up to Date and Stay Informed

Sign up for email alerts to receive company updates including press releases, filings and special announcements straight to your inbox.

Sign me up for:

Latest Financial Results

Q3 2020

Quarter Ended Sep 30, 2020

Latest 10-K

Fiscal Year Ended Dec 31, 2019

View Latest 10-K

Stock Information

Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

Corporate Presentation -  January 2021

Corporate Presentation - January 2021

Download Corporate Presentation - January 2021


Having accumulated decades of collective experience across a variety of fields, our leadership team is the source of our success.

Investor Contact Information


Cellectar Biosciences, Inc.
100 Campus Drive, Suite 207
Florham Park, NJ 07932
T: 608-441-8120
F: 608-441-8121

Investor Relations

LifeSci Advisors
Monique Kosse
Managing Director
T: 212-915-3820

Transfer Agent

American Stock Transfer
Tamara Cajuste
Relationship Manager
6201 15th Avenue
Brooklyn, NY 11219
T: 718-921-8300 ext. 6462
M: 347-939-9659
F: 718-765-8712

Market Data copyright © 2021 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.